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Abstract
The burden of late effects among Hodgkin lymphoma (HL) survivors treated according 
to contemporary protocols remains poorly characterized. We used nation‐wide registers 
to assess number of inpatient bed‐days and specialist outpatient visits among 1048 HL‐
patients (<25 years, diagnosed 1990‐2010) and 5175 country‐, sex‐, and age‐matched 
comparators. We followed them for up to 24 years, with time‐dependent assessment of 
relapse status. International Classification of Diseases (ICD‐10) chapter‐specific hazard 
ratios (HRs) were assessed in Cox regression analyses, and nonparametric statistics 
described patterns of health‐care‐use. Relative to comparators, relapse‐free survivors 
were at increased risk of infections, diseases of the blood, endocrine, circulatory and 
respiratory systems, and unspecific symptoms, HRs ranging from 1.86 to 3.05. Relative 
to comparators, relapsed survivors had at statistically significantly increased risk of dis-
eases reflecting practically all investigated disease‐chapters, HRs ranging from 1.60 to 
18.7. Among relapse‐free survivors, 10% of the patients accounted for 80% of all hos-
pital bed days, and 55% were never hospitalized during follow‐up. Among relapsed‐
survivors, 10% of the patients accounted for 50% of the bed days, and only 24% were 
never hospitalized during follow‐up. In contrast, 10% of the comparators accounted for 
90% of hospital bed days and 75% were never hospitalized. These findings challenge 
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1 |  INTRODUCTION
Modern therapy for Hodgkin lymphoma (HL) offers cure 
rates exceeding 90%.1-3 A general impression is that a high 
price for HL cure entails of a high risk of adverse treatment 
effects.3-6 Consequently, endeavors are continuously ongo-
ing to define treatment regimens that have fewer late effects 
while maintaining the high cure rates.7
Numerous investigations have addressed risk factors for 
late morbidity among survivors of cancer at young ages.8-13 
While the spectrum of late effects of treatment is likely 
to vary among HL survivors treated before and after the 
early, or mid 1990s owing to changes in therapy,14,15 it 
is clear from literature that morbidity is elevated among 
HL survivors compared with the general population, and 
that the risk depends on intensity and type of treatment. 
However, although relevant both to patients and for health 
care planners, little is known about how this disease burden 
is distributed among survivors, particularly not between re-
lapsing and relapse‐free patients.
Efforts to identify late effects from treatments may benefit 
from observational studies16 when population‐based cohorts 
with long‐term follow‐up and complete coverage of outcome 
data exist.
In addition, treatment comparisons are possible if ad-
ministrative circumstances dictate protocol choice, as is 
often the case for HL among adolescents and young adults 
(AYA). For instance, both in Sweden and Denmark pa-
tients at opposite ends of the AYA age spectrum are treated 
according to pediatric and adult protocols, respectively, 
differing with regard to both drugs used and radiation cri-
teria. At the same time, radiotherapy has historically been 
more common in young Swedish HL patients compared to 
Danish HL patients, adding another dimension to treatment 
variation.17
To advance the understanding of HL survivor morbidity, 
we assessed use of out‐ and inpatient care in a population‐
based contemporarily treated cohort of children, adoles-
cents, and young adults diagnosed with HL in Denmark 
and Sweden with detailed information on treatment and 
relapse and contrasted with a matched sample of general 
population comparators.
2 |  MATERIALS AND METHODS
2.1 | Study population, comparators, and 
setting
Our study cohort has been described previously.2,17,18 
Briefly, through hospital file review and population‐based 
hospital‐, cancer‐, and lymphoma registers we identified all 
individuals diagnosed with HL before the age of 25 years in 
the period 1992‐2009 in Sweden and 1990‐2010 in Denmark. 
Available data included information on nationality, gender, 
date of birth and diagnosis, Ann Arbor disease stage at di-
agnosis, primary treatment and outcome, and when present 
and relevant, relapse treatment, and outcome. Treatment in-
formation for Danish children was from medical records, 
for Swedish children from the Swedish Childhood Cancer 
register and for adults in both Denmark and Sweden treat-
ment information came from the Nationwide lymphoma 
registers. In addition, missing information was in selected 
cases identified through medical record review and added 
to the lymphoma registers and Swedish Childhood Cancer 
register prior to linkage to the cause of death and national 
hospital registers. For each patient we identified up to five 
comparators in the Swedish and Danish population‐regis-
ters, respectively, who were matched to the index patient on 
country, sex and age at diagnosis, and alive and free from 
HL at diagnosis of the index patient.19,20 The matched com-
parators were followed from the corresponding diagnosis 
date of the index patient.
2.2 | Outcomes
Using the personal identification number unique to all indi-
viduals in Sweden and Denmark, we linked the cohorts of HL 
patients and comparators to national population—and cause 
of death registers19,20 to ascertain vital status, to national hos-
pital registers21,22 to ascertain information on hospital care 
following HL treatment and corresponding time windows for 
the comparators, and to the national cancer registers23,24 to 
ascertain secondary malignancies among the HL patients.
The outcome data was retrieved for the calendar years 
1994‐2014 (Denmark) and 1997‐2012 (Sweden), defining 
the (country‐specific) study periods when inpatient and spe-
cialist outpatient diagnosis registration were nation‐wide 
the impression of a uniformly distributed long‐term morbidity among all HL survivors 
and emphasize the need for early identification and attention to patients particularly 
susceptible to late effects, such as relapsed survivors.
K E Y W O R D S
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and according to the International Classification of Diseases 
revision 10 (ICD 10) in both countries. In Sweden informa-
tion on diagnoses relating to outpatient visits was available 
only from 2001, and accordingly the Swedish contribution 
to the outpatient visit analyses was restricted to the period 
2001‐2012. We grouped diseases in inpatient and outpa-
tient registrations according to ICD chapters,25 excluding 
diagnoses in chapters XV, XVI, XVII, XX, XXI, XXII: that 
is, diagnoses related to pregnancy, malformations, the peri-
natal period, and external causes of morbidity, since we did 
not consider those as treatment complications26 (Table S1). 
The disease group: “Symptoms” includes symptoms, signs 
or abnormal clinical and laboratory findings not elsewhere 
classified. Furthermore, we disregarded all outpatient vis-
its with HL/HL relapse or non‐HL (C81‐C85) as main 
diagnosis (assumed to represent clinical check‐up visits). 
Finally, we aggregated chapters VI, VII, and VIII under 
the heading central nervous system (CNS) morbidity due 
to small numbers.
2.3 | Follow‐up
We followed patients and comparators from time of primary 
HL diagnosis or start of study period, whichever occurred 
last, until the end of the study period, death or the relevant 
outcome in incidence analyses, whichever occurred first.
We stratified patients according to baseline character-
istics and first‐line treatment modalities. We assumed pri-
mary HL and HL relapse treatment took place in the 1‐year 
period following the diagnosis or relapse to distinguish 
hospitalizations related to HL treatment. Thus, we stratified 
follow‐up time according to time since primary diagnosis 
(0, 1‐3, 4‐6, 7‐9, 10‐12, 13+ years), and according to time 
since first relapse, that is, 0, 1+ years since relapse. Using 
combinations of these time intervals (states) patients were 
time‐dependently grouped into four strata: relapse‐free pa-
tients under treatment, relapse‐free patients post treatment, 
denoted relapse‐free survivors, relapsed patients under re-
lapse treatment and relapsed patients post‐relapse treatment, 
F I G U R E  1  Hazard ratios with 95% confidence intervals (CI) for inpatient hospitalizations due to specific disease‐chapters for Hodgkin 
lymphoma patients and comparators, stratified by relapse status. Hazard ratios for incidence of inpatient hospitalization by International 
Classification of Diseases (ICD)‐chapters for Hodgkin lymphoma patients (<25 y) diagnosed 1990‐2009 in Sweden and Denmark and matched 
comparators. Relapse‐free survivors are indicated by red diamonds, relapsed survivors by blue triangles and comparators, the reference group by 
green squares. Lines indicate 95% CI. Specific ICD‐codes are indicated in Table S1. Abbreviations: Blood, Blood disorders; CNS, Central Nervous 
system disorders; Symptoms, Unspecified symptoms
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denoted relapsed survivors. Comparators and their follow‐
up time were assigned to the same stratum as their index 
person to allow comparison with the background popula-
tion. Thus, any patient or their matched comparators would 
contribute follow‐up time and outcomes to at least one of 
these four strata, and at most all four strata during follow‐
up, but only to one stratum at a time.
We prepared outcome data for two distinct types of anal-
yses assessing (a) incident outcomes, that is, first occurrence 
of diagnoses in broad groups (Figures 1 and S1‐S4), and (b) 
descriptive characteristics of hospital use based on total num-
ber of inpatient admissions and bed days and outpatient visits 
per time‐period of follow‐up (Tables 2 and S2; Figures 2-4).
2.4 | Statistical analyses
Comparisons of incidence rates of ICD chapter‐specific dis-
eases among different patient groups (including population 
controls) in terms of hazard ratios (HRs) and 95% confidence 
intervals (CI) were performed as a series of independent un-
adjusted Poisson regression analyses over follow‐up time 
intervals defined by time since primary HL diagnosis. The 
incidence of non‐HL malignancies after diagnosis/pseudo‐di-
agnosis in patients and controls was analyzed using Poisson 
regression, presenting hazard ratios with likelihood‐ratio 
based confidence intervals. Follow‐up was from diagnosis/
pseudo‐diagnosis or 1 January 1994 (Denmark) or 1 January 
1997 (Sweden), whichever occurred later until the occur-
rence of malignancy studied, death, or end of study, which-
ever occurred first.
Comparisons regarding number and length of inpatients 
admissions, bed days and number of outpatient visits and de-
rivatives thereof were descriptive and nonparametric.
We chose to illustrate the distribution of hospital bed 
days and outpatient visits among the HL patients and com-
parators by means of Lorenz curves,27 traditionally used to 
display inequality in the distribution of income, wealth or 
other resources in a population. For reasons of presenta-
tion we have inverted one of the axes in this construction, 
thereby in Figures 3 and 4 producing “inverted Lorenz 
curves” regarding the use of bed days and outpatient vis-
its. The information content is the same as for the original 
Lorenz curves.
All analyses were performed in SAS version 9.4.
3 |  RESULTS
Overall, we followed 1048 HL patients and 5175 country‐, 
sex‐, and aged‐matched comparators (Table 1). Overall there 
were equally many male and female patients. There were 
more males than females in the youngest age groups (patients 
treated in pediatric departments), and, conversely, more fe-
males than males in the older age groups (patients treated in 
adult departments). Slightly less than half (47%) of the pa-
tients presented with limited stage disease (I‐IIA) (Table 1). 
Again, there was some variation by age with advanced stage 
(IIB‐IV) being most common in the young adult group.
Overall, 140 patients (12%) experienced relapse following 
primary treatment, including nine patients who did not re-
spond during primary treatment or relapsed within 3 months 
and were considered primarily progressive. For relapsing 
patients, the median time from diagnosis to relapse was 
1.1  years (range: 0.1‐16.5) and the median follow‐up time 
from relapse was 6.7 years (range: 0.1‐20.0).
3.1 | Frequencies of hospitalizations
We characterized patterns of hospital care by tabulating 
frequencies of hospital admissions and their durations for 
comparators, relapse‐free, and relapsed survivors in periods 
F I G U R E  2  Inpatient hospitalizations for Hodgkin lymphoma 
(HL) patients and comparators, stratified by relapse status. Inverted 
Lorenz curve showing inverted cumulative percentage frequency 
distributions of bed days spent in hospital by HL relapse‐free 
survivors, relapsed survivors and population‐comparators (see text for 
definitions). The X axis shows decreasing deciles of bed days spent 
in hospital during the entire follow‐up by members of the respective 
cohorts and the Y axis the cumulative proportion of all bed days 
in hospital during the entire follow‐up for the entire cohort that are 
accounted for by patients at the relevant decile. Hospital contacts 
due to pregnancy, childbirth, conditions in the perinatal period and 
congenital malformations were ignored. The reference line illustrates 
that the 10% of the individuals who had spent most days in hospital 
accounted for approximately 90%, 80%, and 50% of the total number 
of bed days accumulated by the comparators, relapse‐free, and relapsed 
survivors, respectively
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more than 1 year after primary diagnosis or relapse‐diagno-
sis (Table 2). Among the comparators 25% had one or more 
hospitalizations during follow‐up while 75% were never hos-
pitalized. Among relapse‐free 45% had one or more hospi-
talizations and 55% were never hospitalized. Among relapsed 
76% had one or more hospitalization more than one year after 
primary‐ or relapse‐diagnosis and only 24% were never hos-
pitalized. In addition, except for individuals experiencing 
more than 10 hospitalizations during follow‐up, hospitaliza-
tions tended to be longer for relapsed survivors than for com-
parators and relapse‐free survivors (Table 2).
3.2 | Second cancers among patients
Among the HL patients, 35 experienced secondary ma-
lignancies, corresponding to a hazard ratio compared to 
controls of 3.00 with 95% CI of 1.95‐4.54. The second-
ary malignancies included six cases of cervix cancer 
(HR  =  1.04;95% CI:0.39‐2.35), six cases of breast can-
cer (14.7;3.38‐100), three cases of myelodysplastic syn-
drome or acute myeloid leukemia (14.6;1.86‐296) and 
nine cases of skin cancer (4.89;1.91‐12.5). Six HL pa-
tients experienced a secondary malignancy after a relapse 
(9.30;2.66‐36.4).
3.3 | Risk of disease‐specific hospitalizations
We compared incident discharge diagnoses grouped by 
ICD‐10 chapters between comparators, relapse‐free, and 
relapsed survivors (Figure 1). These analyses showed that 
relative to comparators, relapse‐free survivors were at in-
creased risk of inpatient hospitalizations for infections, 
for diseases of the blood, endocrine, circulatory, and res-
piratory system disorders and for unspecified symptoms. 
Meanwhile, relative to comparators relapsed survivors had 
increased risk of being hospitalized for conditions across 
the entire spectrum of diseases with the exception of mental 
disorders (Figure 1).
Comparisons between patients with different disease 
stages, reflecting also the burden of therapy (Figure S1) or 
types of treatment: pediatric vs adult department (Figure S2), 
radiotherapy vs no radiotherapy (Figure S3) and 1‐4 cycles 
of chemotherapy vs 5‐8 cycles of chemotherapy (Figure S4) 
produced mostly inconspicuous/small differences.
F I G U R E  3  Specialist outpatient visits for Hodgkin lymphoma 
(HL) patients and comparators by relapse status. Inverted Lorenz 
curves showing inverted cumulative percentage frequency 
distributions of number of outpatient visits paid by HL relapse‐free 
survivors, relapse survivors, and population‐comparators (see text 
for definitions). The X axis shows decreasing deciles of outpatient 
visits by members of the respective cohorts and the Y axis the 
cumulative proportion of all outpatient visits for the entire cohort 
that are accounted for by patients at the relevant decile. Outpatient 
contacts only due to pregnancy, childbirth, conditions in the perinatal 
period and congenital malformations were ignored. The reference line 
illustrates that the third of the most frequently admitted individuals 
accounted for 90%, 80%, and 80% of all outpatient visits accumulated 
by the comparators, relapse‐free, and relapsed survivors, respectively
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F I G U R E  4  Number and proportion of patients contributing to 
used bed days and outpatient visits. Percentage of patients contributing 
person time and proportions of bed days (red bars) and specialist 
outpatient visits (green bars) stratified by follow‐up time for relapse 
survivors. Relapse‐free survivors contributed to the rest of the bed 
days and outpatient visits adding up to a 100% (see text for definitions 
of relapsed and relapse‐free) patients. The 10% of the patients with 
a relapse contributed to about a half of the number of bed days the 
patients used during years 1‐6 and about 20% from year 7. They also 
contributed to about 20% of the outpatient visits except during the first 
3 y and after 13 y of follow‐up
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3.4 | Distribution of hospital care among 
patients and comparators
We illustrated use of hospital care in the period more than 
1  year after diagnosis or relapse diagnosis by showing 
distributions of bed days and outpatient visits, respectively, 
for each of the studied cohorts (Figures 2 and 3).
Hospital care was unevenly distributed among both com-
parators, relapse‐free, and relapsed survivors with a small pro-
portion of individuals accounting for most of the respective 
T A B L E  1  Characteristics of patients and matched comparators, showing person years and numbers contributing to a given follow‐up stratum
Baseline 
characteristics
All patients
Pediatric Depta 
0‐15 Den 0‐18 Swe
Adult Depta 
15‐25 Den, 18‐25 Swe Comparatorsb
N (%) PY N (%) PY N (%) PY N (%) PY
Overall 1048 11591 318 3469 730 8122 5175 56492
Mean follow‐up 
overall (Years)
  (11.1)   (10.9)   (11.1)   (10.9)
Gender                
Females 524 (50) 5622 147 (46) 1613 377 (52) 4009 2585 (50) 27859
Males 524 (50) 5969 171 (54) 1856 353 (48) 4113 2590 (50) 28633
Country                
Denmark 450 (43) 5429 90 (28) 1012 360 (49) 4416 2250 (43) 26361
Sweden 598 (57) 6163 228 (72) 2457 370 (51) 3706 2925 (57) 30131
Stage                
I‐IIA 492 (47) 5650 156 (50) 1693 336 (46) 3957 — —
IIB‐IV 547 (52) 5822 159 (50) 1737 388 (54) 4084 — —
Radiotherapy (RT)                
No RT 335 (34) 3434 110 (36) 1092 225 (33) 2341 — —
Given RT 646 (66) 7636 193 (64) 2250 453 (67) 5386 — —
Chemotherapy                
2‐4 courses 465 (48) 5001 222 (71) 2298 243 (37) 2703 — —
6‐8 courses 499 (52) 5705 90 (29) 1096 409 (63) 4608 — —
Time dependent 
characteristicsc
All patients
Pediatric Depta 
0‐15 Den 0‐18 Swe
Adult Depta 
15‐25 Den, 18‐25 Swe Comparatorsb
N (%) PY N (%) PY N (%) PY N (%) PY
Relapsedd                
No 1039 (88)d 10539 317 (89) 3197 722 (88) 7342 — —
Yes 140 (12) 1052 40 (11) 273 100 (12) 780 — —
Time since 
 diagnosisb (years)
               
0 910 (20) 885 269 (19) 258 641 (20) 627 4490 (20) 4369
1‐3 1012 (22) 2772 302 (21) 817 710 (22) 1955 5000 (22) 13741
4‐6 965 (21) 2608 287 (20) 769 678 (21) 1840 4773 (21) 12874
7‐9 777 (17) 2044 231 (16) 621 546 (17) 1423 3832 (17) 9954
10‐12 587 (13) 1473 185 (13) 473 402 (12) 1000 2817 (12) 7026
13+ 390 (8) 1808 132 (9) 532 258 (8) 1277 1845 (8) 8529
Abbreviations: Den, Denmark; N, Number; PY, person years of follow up; Swe, Sweden.
aThe age limit is set to 15 years in Denmark and 18 years in Sweden due to treatment traditions in the respective countries. These country‐specific administrative 
boundaries between pediatric and adult departments are rarely violated in clinical practice. 
bFor comparators diagnosis should be interpreted as index date. 
cThe number of relapsed and non‐relapsed patients adds to > 1048 and change over time since a person start as non‐relapsed and move to the relapsed group at the date 
of relapse, the numbers indicate the number of individuals contributing to each given cell. The corresponding comparators move group as their corresponding case 
move group. 
dNine patients relapsed before start of follow‐up explaining the reduction from 1048 to 1039 in the time dependent characteristics. 
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cohorts’ total (cumulative) number of bed days and outpatient 
visits, respectively (Figures 2 and 3). However, the degree of 
unevenness differed between patient groups and comparators. 
For example, the 10% of the individuals (supportive line in 
Figure 2) who had spent the most days in hospital accounted 
for approximately 90%, 80%, and 50% of the total number 
of bed days accumulated by the comparators, relapse‐free, 
and relapsed survivors, respectively. Similarly, the one‐third 
(supportive line in Figure 3) of the most frequently admitted 
individuals accounted for 90%, 80%, and 80% of all outpa-
tient visits accumulated by the comparators, relapse‐free, and 
relapsed survivors, respectively.
We next tabulated all bed days and outpatient visits for 
comparators, relapse‐free, and relapsed survivors in different 
time intervals since primary diagnosis. As shown in Figure 4 
and Table S2, despite being few (10%), the relapsed survivors 
accounted for a disproportionally large burden of health care 
use as reflected in number of days in hospital (bed‐days) as 
compared to all relapse‐free (90%) survivors, especially from 
1 up to the first 6 years after primary diagnosis. Similarly, 
relapsed survivors also accounted for a disproportionate 
number of out‐patient visits in all follow‐up periods except 
possibly 13+ years after primary diagnosis (Figure 4).
4 |  DISCUSSION
We followed a cohort of more than 1000 HL patients di-
agnosed before the age of 25  years to characterize their 
morbidity more than 1 year after primary diagnosis or relapse‐
diagnosis. In agreement with similar studies, we showed that 
compared with the general population, HL survivors are at 
increased risk of being hospitalized for a wide array of dis-
eases. However, our investigation expands the understanding 
of HL survivor morbidity by demonstrating that especially 
patients surviving relapsed disease were at greater risk and 
had more and longer hospitalization than relapse‐free survi-
vors during follow‐up. In addition, among relapse‐free survi-
vors, we demonstrate that disease stage at diagnosis was of 
limited significance for later morbidity. A small proportion 
of relapse‐free survivors accounted for many hospital con-
tacts and likely need care, and close follow‐up, but indeed 
more than half of the relapse‐free survivors were never hos-
pitalized during follow‐up.
We are unaware of other investigations that have pro-
vided similarly detailed insight into the distribution of hos-
pital care among young HL survivors. Hospitalization rates 
have previously been used as a measure of the burden of late 
effects of treatment among young cancer survivors,8-10,28-32 
although only few studies have focused specifically on HL 
patients.10,12,26,33,34 Our finding that the excess hospital use 
among survivors is mainly driven by the relapsing individu-
als is in line with a few other previous investigations.26,35,36 
Results similar to the present study were recently reported 
in a Danish population‐based study of 1768 5‐year survi-
vors of HL, diagnosed at ages 15‐39  years in the period 
1943‐2004.37 That study overlapped with the present inves-
tigation for the subset of 15‐24‐year‐old Danish patients 
diagnosed between 1990 and 2004, who survived their 
disease by 5 years or more, but included neither children, 
nor outpatient data or clinical information, such as disease 
stage, and further, only approximated relapse‐status. The 
calendar years in that study also covered treatments that 
are today outdated.
Our analyses highlight what may only be implicitly un-
derstood from previous studies. Specifically, if number of 
bed days is interpreted as a measure of morbidity, the clini-
cal implication learned is that a small subset of the survivors 
T A B L E  2  Distributions of hospitalizations for patients stratified by relapse status and comparators
Hospitalization 
frequency
N of patients with different number of hospitalizations 
(%)
Mean number of bed days (mean number of bed 
days per hospitalization)
Comparators Relapse‐freea Relapsed Comparators Relapse‐freea Relapsed
0 hospitalization 3832 (75) 533 (55) 30 (24) 0 0 0
1 hospitalization 706 (14) 199 (20) 22 (18) 2 (2.0) 2 (2.2) 3 (3.0)
2‐4 hospitalizations 445 (9) 165 (17) 21 (17) 7 (2.7) 7 (2.7) 11 (3.8)
5‐9 hospitalizations 93 (2) 48 (5) 17 (14) 26 (4.2) 24 (3.7) 36 (5.3)
10+ hospitalizations 49 (1) 26 (3) 33 (27) 124 (6.0) 77 (4.9) 92 (4.1)
1+ (one or more hosp.b) 1293 (25) 438 (45) 93 (76) 10 (3.8) 11 (3.5) 42 (4.2)
Number (left three columns) and length (right three columns) of inpatient admissions more than one year after primary or relapse diagnosis.
Among the comparators 25% had one or more hospitalization during follow‐up while 75% were never hospitalized. Among relapse‐free 45% had one or more hospital-
ization and 55% were never hospitalized. Among relapsed 76% had one or more hospitalization more than 1 y after primary‐ or relapse‐diagnosis and 24% were never 
hospitalized.
Abbreviations: N, Number.
aPlease note that patients start in the not relapsed group and move to the relapsed group at the date of relapse. 
b1+ (a combined group of patients having one or more hospital inpatient admission). 
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appears to be particularly susceptible to late effects of treat-
ment.26 Although the general burden of disease was higher in 
relapse‐free survivors in comparison with the general popula-
tion, more than half of this population was never hospitalized 
during the follow‐up period. Therefore, for most HL survi-
vors, the risk of severe morbidity requiring inpatient care 
may be lower than generally assumed and this message is 
important to communicate to HL patients, families, and care-
givers. Our observation of most of the morbidity pertaining 
to a small minority of the HL patients would in all likelihood 
be supported a fortiori if the patients with the worst prognosis 
could somehow be salvaged from death and thereby contrib-
ute more to our tables and figures.
The present investigation was also inspired by differences 
in HL treatment dictated by administrative and geographi-
cal circumstances, with Swedish children receiving more 
radiotherapy than Danish children.17 Interestingly, however, 
we saw little evidence that these differences were reflected 
in differences in admissions to inpatient and specialist out-
patient care during our follow‐up span. Thus, the different 
treatment recommendations in the countries did not influence 
the burden of late effects. However, despite the rather long 
follow‐up of our investigation, interpretational caution is still 
warranted due to the long lag‐time between given radiother-
apy and severe late adverse effects, such as secondary malig-
nancies and cardiovascular diseases.5,6,12,38
Avoiding a relapse is important not only for the individual 
patient and for immediate survival, but also for future fertil-
ity in survivors39 and from a public health‐care perspective. 
Regarding follow‐up recommendations for HL patients, a 
broad spectrum of diseases seen for relapsing patients show 
the importance of awareness of many side effects, a broad 
follow‐up program and communication between hematolo-
gist/oncologists and other health care providers. An increase 
in risk was seen for infections, blood, endocrine, circulatory, 
and respiratory disorders also in relapse‐free, confirming 
these well‐known treatment side effects and supporting cur-
rent follow‐up recommendations for them.
So far, no randomized trials have investigated differ-
ences in outcome and late effects between adult and pediat-
ric treatment protocols40 and, since HL particularly affects 
the AYA age spectrum, interdisciplinary collaborations 
might further optimize their treatment.41 There are a few 
studies including adolescents in adult trials,42,43 with sat-
isfying treatment results, one describing no difference in 
secondary malignancies (16‐21 vs 22‐45  years), another 
noting them to be more frequent in young adults (21‐45 
vs 15‐20 years). One study has described better event‐free 
survival and overall survival in patients <18 years treated 
according to pediatric protocols,44 with no data on late 
adverse effects. The lack of any significant differences in 
frequency of late adverse effects in the first decade after 
primary treatment among patients treated in pediatric and 
adult departments and also relatively few secondary malig-
nancies indicates that the different strategies result in the 
same long‐term outcome. However, since some late‐effects, 
in particular secondary malignancies, have an incubation 
period of 20‐30 years, we cannot rule out that differences 
will eventually emerge.
Our investigation has several strengths but also limita-
tions. A major strength is its population‐based approach 
with available detailed clinical information on patients 
treated according to modern protocols. We also relied on 
high quality registers for outcome ascertainment as al-
most all in‐ and outpatient specialist care in Sweden and 
Denmark are publicly funded and therefore subject to man-
datory documentation. Weaknesses include that we were 
not able to reliably identify second or third relapses, which 
probably account for some of the excess hospital care re-
quired by the relapsing patients. However, the differences 
observed between relapse‐free and relapsed patients may 
also be underestimated due to a higher mortality among 
the relapsed patients. Finally, we limited follow‐up to pe-
riods when registers in both countries used ICD10 classi-
fications. Because a proportion of patients were diagnosed 
before the introduction of the classification, our analyses 
are encumbered by an element of left‐truncation.
5 |  CONCLUSIONS
The majority of survivors after young HL had few or no in-
patient bed‐days after the primary treatment, whereas a small 
number of individuals were heavily burdened by late morbid-
ity. Patients surviving disease relapse accounted for a dis-
proportionately large share of bed‐days accrued by the entire 
HL patient cohort. Relapse‐free patients with different initial 
stages, different treatment concepts and treatment in a pedi-
atric or adult department had on the other hand very similar 
future late morbidities. Relapse and the consequences from 
relapse treatment seem most important to avoid also from 
a future health care use perspective and these patients need 
extra attention during follow‐up.
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